Literature DB >> 31445183

T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.

Fabienne Lucas1, Michael Pennell2, Ying Huang1, Don M Benson1, Yvonne A Efebera1, Maria Chaudhry1, Tiffany Hughes1, Jennifer A Woyach1, John C Byrd1, Suohui Zhang3, Desiree Jones1, Xiangnan Guan3, Christin E Burd3, Ashley E Rosko4.   

Abstract

Autologous stem cell transplant (ASCT) is the standard of care for patients with multiple myeloma (MM). The clinical significance of peripheral blood T lymphocyte (PBTL) immunologic changes associated with ASCT is poorly understood. Here we evaluated T cell transcriptional messenger RNA profiles and immunophenotypes to correlate immunologic senescence, exhaustion, and anergy with clinical endpoints in a cohort of patients with MM undergoing ASCT. ASCT induced global transcriptional T cell changes and altered molecular levels of markers of T cell subtypes, T cell activation, and exhaustion. These included reduced CD4/CD8 ratio, skewing toward the Th1 subset, reduced expression of costimulatory receptors CD27 and CD28, heightened T cell activation, and increased expression of immune modulatory molecules LAG3 and PD1. Multicolor flow cytometry experiments confirmed altered circulating CD4 and CD8 subsets and skewing toward differentiated effector cells. Moreover, ASCT promoted an exhausted immunophenotype in CD3+CD4+ subsets and a senescent immunophenotype in CD3+CD8+ subsets. Subset-specific altered expression was also seen for surface molecules with immunomodulatory function. ASCT affected soluble levels of molecules with immunomodulatory function by increasing plasma HVEM and TIM3. High molecular LAG3 level was associated with inferior event-free survival post-ASCT (hazard ratio = 5.44; confidence interval, 1.92 to 15.46; P = .001; adjusted P [controlling for false discovery rate] = .038). Using a comprehensive evaluation of PBTLs on a molecular and phenotypic level, we have identified that ASCT induces global T cell alterations with CD4 and CD8 subset-specific changes. Moreover, LAG3 emerged as an early biomarker of adverse events post-ASCT. These findings will support the development of treatment strategies targeting immune defects in MM to augment or restore T cell responses.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autologous stem cell transplant; Exhaustion; LAG3; Multiple myeloma; Senescence

Year:  2019        PMID: 31445183      PMCID: PMC6952061          DOI: 10.1016/j.bbmt.2019.08.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  36 in total

1.  Dysfunctional T regulatory cells in multiple myeloma.

Authors:  Rao H Prabhala; Paola Neri; Jooeun E Bae; Pierfrancesco Tassone; Masood A Shammas; Charles K Allam; John F Daley; Dharminder Chauhan; Elizabeth Blanchard; Hemant S Thatte; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Authors:  H Suen; R Brown; S Yang; C Weatherburn; P J Ho; N Woodland; N Nassif; P Barbaro; C Bryant; D Hart; J Gibson; D Joshua
Journal:  Leukemia       Date:  2016-04-22       Impact factor: 11.528

3.  IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.

Authors:  Julian Plaumann; Melanie Engelhardt; Mohamed H S Awwad; Hakim Echchannaoui; Eva Amman; Marc S Raab; Jens Hillengass; Niels Halama; Brigitte Neuber; Carsten Müller-Tidow; Hartmut Goldschmidt; Michael Hundemer
Journal:  Cancer Immunol Immunother       Date:  2018-08-20       Impact factor: 6.968

Review 4.  Molecular and cellular insights into T cell exhaustion.

Authors:  E John Wherry; Makoto Kurachi
Journal:  Nat Rev Immunol       Date:  2015-08       Impact factor: 53.106

Review 5.  Induction and stability of the anergic phenotype in T cells.

Authors:  Rut Valdor; Fernando Macian
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

6.  Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma--an analysis from the Austrian Myeloma Registry.

Authors:  Wolfgang Willenbacher; Ella Willenbacher; Claudia Zelle-Rieser; Rainer Biedermann; Roman Weger; Karin Jöhrer; Andrea Brunner
Journal:  Leuk Lymphoma       Date:  2015-11-16

Review 7.  Th1/Th2 cells in patients with multiple myeloma.

Authors:  Hirokazu Murakami; Hatsue Ogawara; Handa Hiroshi
Journal:  Hematology       Date:  2004-02       Impact factor: 2.269

Review 8.  Immunodeficiency and immunotherapy in multiple myeloma.

Authors:  Guy Pratt; Oliver Goodyear; Paul Moss
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

9.  PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients.

Authors:  Anne-Marit Sponaas; Rui Yang; Even Holth Rustad; Therese Standal; Aud Solvang Thoresen; Camilla Dao Vo; Anders Waage; Tobias S Slørdahl; Magne Børset; Anders Sundan
Journal:  Oncotarget       Date:  2018-08-10

10.  Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.

Authors:  Shang-Yi Huang; Hsiu-Hsia Lin; Chung-Wu Lin; Chi-Cheng Li; Ming Yao; Jih-Luh Tang; Hsin-An Hou; Woei Tsay; Sheng-Je Chou; Chieh-Lung Cheng; Hwei-Fang Tien
Journal:  Oncotarget       Date:  2016-09-20
View more
  16 in total

Review 1.  Aging-associated immune system changes in multiple myeloma: The dark side of the moon.

Authors:  Alissa Visram; Taxiarchis V Kourelis
Journal:  Cancer Treat Res Commun       Date:  2021-11-20

2.  T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells.

Authors:  Anthony M Battram; Aina Oliver-Caldés; Maria Suárez-Lledó; Miquel Lozano; Miquel Bosch I Crespo; Núria Martínez-Cibrián; Joan Cid; David F Moreno; Luis Gerardo Rodríguez-Lobato; Alvaro Urbano-Ispizua; Carlos Fernández de Larrea
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-22       Impact factor: 5.849

Review 3.  Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Zaid Al-Kadhimi; Luciano J Costa; Theresa Hahn; Parameswaran Hari; Jens Hillengass; Allison Jacob; Nikhil C Munshi; Stefania Oliva; Marcelo C Pasquini; Qian Shi; Edward A Stadtmauer; Stephanie L Waldvogel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-14       Impact factor: 5.742

Review 4.  Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Alan Howard; David Avigan; Manisha Bhutani; Adam D Cohen; Luciano J Costa; Madhav V Dhodapkar; Francesca Gay; Nicole Gormley; Damian J Green; Jens Hillengass; Neha Korde; Zihai Li; Sham Mailankody; Paola Neri; Samir Parekh; Marcelo C Pasquini; Noemi Puig; G David Roodman; Mehmet Kemal Samur; Nina Shah; Urvi A Shah; Qian Shi; Andrew Spencer; Vera J Suman; Saad Z Usmani; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

Review 5.  CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?

Authors:  Alexandra M Miggelbrink; Joshua D Jackson; Selena J Lorrey; Ethan S Srinivasan; Jessica Waibl-Polania; Daniel S Wilkinson; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2021-06-14       Impact factor: 12.531

6.  Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma.

Authors:  Harsh Parmar; Morie Gertz; Emilie Ingrid Anderson; Shaji Kumar; Taxiarchis V Kourelis
Journal:  Blood Adv       Date:  2021-04-13

7.  LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.

Authors:  Christian Sordo-Bahamonde; Seila Lorenzo-Herrero; Ana P González-Rodríguez; Ángel R Payer; Esther González-García; Alejandro López-Soto; Segundo Gonzalez
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 8.  The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

Authors:  Sarah A Holstein; Nizar Bahlis; P Leif Bergsagel; Manisha Bhutani; Niccolo Bolli; Carrie Brownstein; Pierre Demolis; David Foureau; Francesca Gay; Irene M Ghobrial; Nicole Gormley; Jens Hillengass; Martin Kaiser; Marcela V Maus; J Joseph Melenhorst; Maximilian Merz; Michael O Dwyer; Bruno Paiva; Marcelo C Pasquini; Nina Shah; Sandy W Wong; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2021-06-06

9.  Identification of the immune checkpoint signature of multiple myeloma using mass cytometry-based single-cell analysis.

Authors:  Jinheng Wang; Yongjiang Zheng; Chenggong Tu; Hui Zhang; Karin Vanderkerken; Eline Menu; Jinbao Liu
Journal:  Clin Transl Immunology       Date:  2020-04-29

Review 10.  Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.

Authors:  Helmi Alfarra; Jackson Weir; Stacy Grieve; Tony Reiman
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.